Statement: There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood.
Primary_evidence: Adverse Events 1:   Total: 102/403 (25.31%)   Anaemia 1/403 (0.25%)   Febrile neutropenia 1/403 (0.25%)   Granulocytopenia 0/403 (0.00%)   Neutropenia 1/403 (0.25%)   Thrombocytopenia 1/403 (0.25%)   Cardiac failure 1/403 (0.25%)   Vertigo 1/403 (0.25%)   Hypercalcaemia of malignancy 0/403 (0.00%)   Vision blurred 1/403 (0.25%)   Abdominal discomfort 0/403 (0.00%)   Abdominal pain 4/403 (0.99%) Adverse Events 2:   Total: 41/184 (22.28%)   Anaemia 2/184 (1.09%)   Febrile neutropenia 7/184 (3.80%)   Granulocytopenia 1/184 (0.54%)   Neutropenia 2/184 (1.09%)   Thrombocytopenia 1/184 (0.54%)   Cardiac failure 0/184 (0.00%)   Vertigo 0/184 (0.00%)   Hypercalcaemia of malignancy 1/184 (0.54%)   Vision blurred 0/184 (0.00%)   Abdominal discomfort 1/184 (0.54%)   Abdominal pain 3/184 (1.63%)